The prognosis of metastatic melanoma is poor with a median survival of 6-8 months (Balch et al., 1989) . Chemotherapy achieves only 15-25% objective response rates (Balch et al., 1989) . Immunotherapy protocols based either on alpha-interferon or interleukin 2 (IL-2) alone or associated with lymphokine-activated killer (LAK) cells have not produced major changes, since the overall objective response rates have remained at 15-35% and the duration of responses obtained is usually short (Kirkwood and Ermstoff, 1986; .
Growing tumour-infiltrating lymphocytes (TILs) in vitro frequently allows the generation of CD3+ CD8+ cytotoxic T lymphocytes (CTLs), which may induce a selective lysis of autologous tumour cells in 30% of patients with melanoma Itoh et al., 1988; Topalian et al., 1989) . A second population of CD3+ CD4+ cells can also be established, and these TlLs, have the ability to release or activate cytokines (Fossati et al., 1988) . By using labelled TILs, a substantial accumulation at the tumour site has been described for humans (Fisher et al., 1989) . The adoptive transfer of TILs has proved to be capable of mediating the regression of lung micrometastases from various tumour types in experimental animal models, and a relationship between the degree of response and the number of TILs infused has been reported in experimental systems .
The first trial with TILs administered concomitantly with IL-2 resulted in a 55% response rate in 20 patients with melanoma (Rosenberg et al., 1988; Topalian et al., 1988) ; nevertheless, subsequent studies were unable to show any significant increase in an objective response rate over treatment with IL-2 alone (Kradin et al., 1989; Dillman et al., 1991; Hanson et al., 1991; Markowitz et al., 1991) .
The toxicity related to TIL infusion has been established in patients with lung cancer (Kradin et al., 1987) and renal cell carcinoma (Bukowski et al., 1991) . In these instances, TILs were administered either as a single infusion or as a repeated infusion with fewer than I x 1010 cells per infusion. The side-effects observed were minor or mild and limited to fever, chills, nausea, decrease in vital capacity at respiratory tests. When TILs were administered together with IL-2, each infusion generally contained more than 10'0 cells and the toxicity was mainly related to the high dose of IL-2 (Rosenberg et Topalian et al., 1988; Kradin et al., 1989; Bukowski et al., 1991; Dillman et al., 1991; Hanson et al., 1991; Markowitz et al., 1991 (1) 1(2) 2(9) 1(5) 2(4) Headache 1(3) 3(5) Nausea/vomiting (2) 1(2) 2(3) I)iarrhoea 1(2) 1(1) Hypotension (2) 1(1) (2) 1(4) 4(7) Pericarditis 1(l) 1(1) Dyspnoea 1 (2) 1 (1) Agitation/anxiety (3) 1 (1) Coagulopathy 1(4)
Local inflammation or softening at tumour site 1(1) 1(2) 1(1) Locoregional pain 1 (5) 1 (2) *a, TIL infusion every 3 weeks; b, TIL infusion every 2 weeks; c, TIL infusion every week. At the final analysis of this phase I trial, five patients had died from melanoma, 2-15 months after therapy, while four patients were alive with evidence of disease 8-16 months after the first infusion of TILs.
Imrmmological evahuation Assessment of plasmatic TNF-a, 4-7 days after each infusion, showed a maximum of a 1.2-to 22-fold increase following TIL therapy (Table III) . All patients but one had the maximum level of TNF-a after the last infusion of TIL.
No change was observed in CD45RA, CD45RO, CD25, CD28, CD29W of peripheral blood cells before and after each TILs infusion.
Previous studies of treatment with TILs alone have reported only limited toxicities (Kradin et al., 1987; Bukowski et al., 1991; Marincola et al., 1993) , which did not include grade 3 side-effects. In our study, WHO grade 3 toxic events occurred in six patients after 13/34 infusions. Modifications in arterial blood pres and heart rate were encountered more often in our study than in the NCI trial (21), in which no grade 3 hypotension was seen. In particular, hypotension and accelerated heart rate were more frequent when TILs were infused once a week. Following TIL therapy, a minor pericarditis was detected by a systematic echocardiography after the last infusion in two patients. In each case, the extent of pericarditis was limited and there were no clinical signs.
Compared with other studies (Kradin et al., 1987; Marincola et al., 1993) , the observed increase in frequency and severity of these side-effects could be due to the larger number of cells infused (Kradin et al., 1987) and to a longer period of follow-up after TIL infusions (Marincola et al., 1993) . In our study, TILs were administered over a shorter period of time (15-30min) compared, for example, with 30-60 min infusion time in the NCI study. Considering TIL infusions without subsequent IL-2 treatment (29/34 infusions), the mean time of maximum changes in arterial blood pressure and heart rate occurred after 4.5 and 3.8 h respectively. (Cole et al.. 1994) .
The benefit of surgical excision after a previous exposure to TILs to produce more autocytotoxic CD8+ T cells in a new TIL culture cannot be assumed from the single patient case in this study. Nevertheless, there was a switch from a predominant CD4+ phenotype (94%) to a CD8+ population: however, no autocytotoxicity could be detected.
Whether or not TILs given to patients are able to induce cytokine secretion and thus activate immunocompetent cells remains unclear. An increase in plasmatic TNF-a could be detected after 4-7 days following TIL infusion. TNF-a is known to have a short half-life (Beutler et al., 1986) and is not usually produced by unstimulated TIL in vitro (Schwartzentruber et al., 1991 : Hom et al., 1993 . However, recent reports have described the release of cytokines, including TNF-a, by in vitro co-culture of TILs with either autologous tumour stimulation (Schwartzentruber et al., 1991) or, more recently, with HLA-matched melanoma tumour cells (Hom et al., 1993) . Secretion of TNF-a after stimulation in vitro followed a lag period and was maximal within the first 24 h (Schwartzentruber et al., 1991) . In this study, TILs given in vivo, and in the absence of exogenous IL-2, were able to induce levels of TNF-a detectable in the serum. At this point, we can only speculate on the nature of this TNF-a increment. Increased levels of TNF-x could be a non-specific phenomenon following infusion of a large number of immune cells; or alternatively, it could reflect a more specific interaction between immune T cells and malignant melanoma antigens.
Following repeated TIL infusions, we did not find any phenotypic changes in the peripheral blood cells. The lack of such changes may suggest that there was no activation of the cells of the immune system in this study, just as reported in a previous report for natural killer. LAK and T cells (CD45RO, CDW29) following single TIL infusion (Bukowski et al., 1991) .
After progression of disease under TIL treatment, the three patients infused together with IL-2 still did not present any objective response. This finding is in contrast to some (Rosenberg et al., 1988; Topalian et al.. 1988) but not other (Dorval et al., 1992) reports claiming that the combination of TIL + IL-2 can reinduce an objective response after failure of IL-2 alone.
In conclusion, repeated infusions of more than 1010 TILs are feasible, without severe side-effects. However, WHO grade 3 side-effects were more frequently observed in this study than in previous trials. No objective tumour response was observed, although some biological changes were noted, including an increase in plasmatic levels of TNF-a. 
